Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18

Section 21

Issuance

Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 21 · current to July 24, 2025 · regulation last amended February 27, 2022

Statute Watch

Get an alert when a bill in Parliament would change this section, and every time it moves.

The text

The Minister must issue a COVID-19 drug authorization if the following requirements are met: (a) the applicant has submitted to the Minister an application that meets the requirements set out in section 20; (b) the applicant has submitted to the Minister any additional information or material requested under subsection 30(1) in the time, form and manner specified under subsection 30(2); and (c) the Minister determines that (i) the use of the drug that is to be tested in the clinical trial will not unduly affect the health or safety of clinical trial subjects or other persons, (ii) the clinical trial is not contrary to the best interests of clinical trial subjects, and (iii) the objectives of the clinical trial are achievable.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗

Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.

Bills in Parliament that would change this section 0

No bill we hold would amend or repeal this section.